Physician profile
Ashraf E Seedhom
NPI 1801870100
$2,203.85
in general payments reported to CMS, 2019-2025
17 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $221 · 2021: $464 · 2022: $277 · 2023: $282 · 2024: $482 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $956.69 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.57 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $215.34 | 2020-2025 | Wainua |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Boston Scientific Corporation | $93.73 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $92.52 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $81.39 | 2023-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $69.18 | 2022-2024 | Mitraclip |
| Merck Sharp & Dohme LLC | $65.23 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $42.61 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $35.20 | 2024 | Arcalyst |
| Cvrx, INC. | $32.37 | 2024 | Barostim Neo System |
| Pfizer INC. | $19.04 | 2024 | |
| Gilead Sciences, INC. | $16.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.39 | 2023 | Inpefa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $16.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Seedhom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.